Bristol Myers Cuts 2026 EPS Outlook To $6.35-$6.55 Even As It Lifts Revenue Guidance

Deal charges of $1,558 million swamped third-quarter earnings, pulling adjusted EPS down to $1.35 from $1.63 on 7% revenue growth.

Share
Bristol Myers Cuts 2026 EPS Outlook To $6.35-$6.55 Even As It Lifts Revenue Guidance

Bristol Myers Squibb raised its 2026 revenue forecast but cut its adjusted earnings-per-share outlook to $6.35-$6.55 from $6.75-$7.00, as $1,558 million in third-quarter charges for licensing deals on unapproved drugs more than doubled the year-earlier $633 million, according to the company's 10-Q filed Thursday.

Revenue up, earnings guidance down

Bristol Myers, the drugmaker behind the cancer drugs Opdivo and Yervoy and the blood thinner Eliquis, now expects full-year revenue of about $49.75 billion to $50.25 billion, up from $49.0 billion to $50.0 billion in July, according to its earnings release.

The EPS cut traces to one line. The guidance now includes a $(0.60) per-share hit from acquired in-process research and development (IPRD, the cost of licensing unfinished drugs) and licensing income, against $(0.02) in July.

Third-quarter adjusted EPS fell to $1.35 from $1.63 even as revenue rose 7% to $13,069 million. The 10-Q blames the higher IPRD charges and the end of royalty income on diabetes products; that income was $286 million in the year-earlier quarter.

Three deals drove the charge

The charges were led by $775 million to Hengrui, $500 million to BioNTech and $250 million in SystImmune milestones. Hengrui's was an upfront fee plus an anniversary payment under licenses for 13 early-stage assets; BioNTech's was the first anniversary payment on its pumitamig collaboration.

The second-quarter 10-Q showed $94 million of IPRD for six months and none in that quarter, so nearly all of the $1,651 million nine-month total landed in the third quarter. The SystImmune milestone is payable in the fourth quarter of 2026.

Newer drugs fill the patent gap

Pomalyst sales fell to $130 million from $675 million and Revlimid to $303 million from $575 million as generics arrived. Eliquis rose 25% to $4,690 million, helped by lower rebates after a U.S. list price cut. The growth portfolio, including Breyanzi, Camzyos and Reblozyl, rose 12% to $7,662 million.

Management expects about $2.0 billion in annual savings by the end of 2027. Nine-month operating cash flow fell to $8,678 million from $12,182 million, and dividends of $0.63 per share totaled $1,288 million declared in the quarter.

The FDA's target decision date for mezigdomide, Bristol Myers' multiple myeloma drug, is May 13, 2027.

Sources

More on Bristol-Myers Squibb

All Bristol-Myers Squibb (BMY) coverage →